NCT00872222终止4 期
Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle™ Acetabular Cup Prosthesis With a Ceramic-on-ceramic Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement
DePuy International1 个研究点 分布在 1 个国家目标入组 98 人开始时间: 2007年1月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 98
- 试验地点
- 1
- 主要终点
- Kaplan-Meier survivorship at the five-year period
研究概览
简要总结
The purpose of this study is to monitor the performance of the Pinnacle™ Cup with a ceramic-on-ceramic bearing combination in the treatment of patients with hip joint disease requiring a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •i) Male or female subjects, aged between 18 and 70 years inclusive.
- •ii) Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.
- •iii) Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
- •iv) Subjects undergoing primary total hip replacement who are suitable for cementless acetabular components.
排除标准
- •i) Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
- •ii) Subjects undergoing revision hip replacement.
- •iii) Women who are pregnant.
- •iv) Subjects who are known drug or alcohol abusers or with psychological disorders that could effect follow-up care or treatment outcomes.
- •v) Subjects who have participated in a clinical study with an investigational product in the last 12 months.
- •vi) Subjects who are currently involved in any injury litigation claims.
- •vii) Subjects undergoing a simultaneous bilateral hip operation.
- •viii) Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip is part of this clinical investigation.
- •ix) Subjects undergoing the second stage of a staged bilateral for whom the contralateral hip was implanted less than six months previously or is not performing satisfactorily
结局指标
主要结局
Kaplan-Meier survivorship at the five-year period
时间窗: 5yrs
次要结局
- Kaplan-Meier survivorship calculations(Annually)
- Radiographic analysis(6mths, 1yr, 2yrs, 5yrs, 7yrs, 10yrs and 15yrs post-surgery)
- Harris Hip Score(6mths, 1yr, 2yrs, 5yrs, 7yrs, 10yrs and 15yrs post-surgery)
- Oxford Hip score(3yrs, 4yrs, 6yrs, 8yrs, 9yrs, 11yrs, 12yrs, 13yrs and 14yrs post-surgery)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
4 期
A Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip ReplacementPost-traumatic ArthritisCollagen DisordersTraumatic Femoral FracturesNonunion of Femoral FracturesRheumatoid ArthritisOsteoarthritisCongenital Hip DysplasiaSlipped Capital Femoral EpiphysisAvascular NecrosisNCT00208429DePuy International
终止
4 期
Multi-centre Study to Assess the Long-term Performance of the Deltamotion Cup System in Primary Hip Replacement SurgeryTraumatic Femoral FracturesCongenital Hip DysplasiaRheumatoid ArthritisOsteoarthritisPost-traumatic ArthritisAvascular NecrosisNCT01635166DePuy International250
已完成
不适用
Fabian Prospective Assessment of Volume Guarantee (Fabian PaVoG)Respiratory Insufficiency in ChildrenNCT05229172Vyaire Medical76
终止
不适用
A Multicentre Trial to Compare Two Articulating Bearing Surfaces as Used in Cementless Primary Hip ArthroplastyOsteoarthritisNCT01247038Zimmer Biomet130
已完成
不适用
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese SubjectsCervical Intraepithelial NeoplasiaNCT03438006GlaxoSmithKline3,016